Pittsburgh Launches Rare Ventures with $25M to Accelerate Rare-Disease Therapies
TL;DR
The Richard King Mellon Foundation is launching Rare Ventures in Pittsburgh with $25 million to create a three-year, venture‑philanthropy hub that unites universities, biotech firms, and EB Research Partnership to accelerate rare-disease drug development. The initiative will use an AI tool called Curator to centralize deidentified patient genetic data for trial matching, with a goal of becoming self‑sustaining by funneling revenues from approved therapies back into future research and expanding collaborations across Pitt, CMU, ElevateBio, UPMC, and Stanford.
- RK Mellon Foundation pledges $25M to launch rare disease therapy hub in Pittsburgh Pittsburgh Post-Gazette
- Exclusive | Most Rare Diseases Have No Approved Drug. This Accelerator Aims to Help WSJ
- Pittsburgh-based start-up targets rare diseases with Mellon Foundation grant that could hit $25M TribLIVE.com
- Rare Ventures, a First-of-its-kind Platform for Accelerating Rare Disease Therapies, Launches in Pittsburgh Carnegie Mellon University
- Pittsburgh set to become rare disease research hub with $25M investment 90.5 WESA
Want the full story? Read the original reporting
Read on Pittsburgh Post-Gazette